Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
Myeloma
Interventions
DRUG

Lenalidomide

10 mg/day in cohort 1, and 25 mg/day in cohort 2. LEN is administered orally in standard 21 day cycles starting one week before each DC injection and ending 14 days after each DC injection. All patients will receive a total of three cycles of LEN.

BIOLOGICAL

Monocyte derived DCs loaded with KRN7000

10 million DCs injected intravenously

Trial Locations (1)

06520

Yale University School of Medicine, New Haven

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Kyowa Kirin Co., Ltd.

INDUSTRY

collaborator

Celgene

INDUSTRY

lead

Yale University

OTHER